154 related articles for article (PubMed ID: 28786105)
41. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
42. Transforming growth factor-alpha: a surrogate endpoint biomarker?
Beenken SW; Hockett R; Grizzle W; Weiss HL; Pickens A; Perloff M; Malone WF; Bland KI
J Am Coll Surg; 2002 Aug; 195(2):149-58. PubMed ID: 12168960
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of vitamin A in the prevention of loco-regional recurrence and second primaries in head and neck cancer.
Jyothirmayi R; Ramadas K; Varghese C; Jacob R; Nair MK; Sankaranarayanan R
Eur J Cancer B Oral Oncol; 1996 Nov; 32B(6):373-6. PubMed ID: 9039219
[TBL] [Abstract][Full Text] [Related]
44. Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer.
Wu X; Gu J; Dong Q; Huang M; Do KA; Hong WK; Spitz MR
Clin Cancer Res; 2006 Dec; 12(23):7194-201. PubMed ID: 17145846
[TBL] [Abstract][Full Text] [Related]
45. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
46. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.
Urba S; Gatz J; Shen W; Hossain A; Winfree K; Koustenis A; Peterson P; Cohen EE
Oral Oncol; 2012 Aug; 48(8):723-9. PubMed ID: 22414289
[TBL] [Abstract][Full Text] [Related]
47. Risk factors for developing a second upper aerodigestive cancer after radiotherapy with or without chemotherapy in patients with head-and-neck cancers: an exploratory outcomes analysis.
Taussky D; Rufibach K; Huguenin P; Allal AS
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):684-9. PubMed ID: 15936546
[TBL] [Abstract][Full Text] [Related]
48. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251).
Kadakia KC; Barton DL; Loprinzi CL; Sloan JA; Otley CC; Diekmann BB; Novotny PJ; Alberts SR; Limburg PJ; Pittelkow MR
Cancer; 2012 Apr; 118(8):2128-37. PubMed ID: 21882176
[TBL] [Abstract][Full Text] [Related]
49. Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.
Park SH; Gray WC; Hernandez I; Jacobs M; Ord RA; Sutharalingam M; Smith RG; Van Echo DA; Wu S; Conley BA
Clin Cancer Res; 2000 Mar; 6(3):847-54. PubMed ID: 10741706
[TBL] [Abstract][Full Text] [Related]
50. [Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha].
Paredes Espinoza M; Lippman SM; Kavanagh JJ; Delgadillo Madrueño F; Paredes Casillas P; Bañuelos Acosta O; Alvarez Márquez V; Buenrostro Ahued MA; de Alba Ayala I; Arias Castro G
Rev Invest Clin; 1994; 46(2):105-11. PubMed ID: 8052740
[TBL] [Abstract][Full Text] [Related]
51. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
[TBL] [Abstract][Full Text] [Related]
52. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up.
Seixas-Silva JA; Richards T; Khuri FR; Wieand HS; Kim E; Murphy B; Francisco M; Hong WK; Shin DM
Arch Otolaryngol Head Neck Surg; 2005 Apr; 131(4):304-7. PubMed ID: 15837897
[TBL] [Abstract][Full Text] [Related]
53. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
[TBL] [Abstract][Full Text] [Related]
54. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
55. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
Argiris A; Li Y; Forastiere A
Cancer; 2004 Nov; 101(10):2222-9. PubMed ID: 15452834
[TBL] [Abstract][Full Text] [Related]
56. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups.
van Zandwijk N; Dalesio O; Pastorino U; de Vries N; van Tinteren H
J Natl Cancer Inst; 2000 Jun; 92(12):977-86. PubMed ID: 10861309
[TBL] [Abstract][Full Text] [Related]
57. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
Rischin D; Peters LJ; O'Sullivan B; Giralt J; Fisher R; Yuen K; Trotti A; Bernier J; Bourhis J; Ringash J; Henke M; Kenny L
J Clin Oncol; 2010 Jun; 28(18):2989-95. PubMed ID: 20479425
[TBL] [Abstract][Full Text] [Related]
58. Use of external beam radiotherapy is associated with reduced incidence of second primary head and neck cancer: a SEER database analysis.
Rusthoven K; Chen C; Raben D; Kavanagh B
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):192-8. PubMed ID: 18078720
[TBL] [Abstract][Full Text] [Related]
59. Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas.
Roberts TJ; Colevas AD; Hara W; Holsinger FC; Oakley-Girvan I; Divi V
Cancer; 2016 May; 122(9):1388-97. PubMed ID: 26969807
[TBL] [Abstract][Full Text] [Related]
60. Synchronous and metachronous head and neck carcinomas.
Schwartz LH; Ozsahin M; Zhang GN; Touboul E; De Vataire F; Andolenko P; Lacau-Saint-Guily J; Laugier A; Schlienger M
Cancer; 1994 Oct; 74(7):1933-8. PubMed ID: 8082099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
